☆ 4.6 Article

Isotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Evaluation

CANCERS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial

Eva Versteijne et al.

Summary: This study investigates the impact of neoadjuvant chemoradiotherapy on the survival of patients with resectable and borderline resectable pancreatic cancer. The results demonstrate that neoadjuvant chemoradiotherapy improves overall survival compared to upfront surgery in these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis

Young Seob Shin et al.

Summary: This study compared the clinical outcomes of stereotactic body radiation therapy (SBRT) with concurrent chemoradiotherapy (CCRT) for locally advanced pancreatic cancer. The results suggest that SBRT could be a feasible alternative to CCRT in treating LAPC patients.

CANCERS (2022)

添加到收藏夹

Article Oncology

Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.

Rainer Fietkau et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma

N. Simoni et al.

Summary: The study evaluated the safety and feasibility of SBRT with SIB/SIP in pancreatic ductal adenocarcinoma patients and found that this method had an excellent toxicity profile in patients, which is significant for improving patients' survival rates.

CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy With On-Table Adaptive Replanning and Elective Nodal Irradiation for Inoperable Pancreas Cancer

Michael D. Chuong et al.

Summary: This study retrospectively analyzed 35 patients with pancreatic cancer treated with SMART, showing improved survival rates and local control with minimal treatment-related toxicities.

PRACTICAL RADIATION ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Cancer statistics for the year 2020: An overview

Jacques Ferlay et al.

Summary: The study briefly reviews the methods and data sources used in compiling the IARC GLOBOCAN cancer statistics for 2020 and summarizes the main results. It estimated that there were nearly 19.3 million new cancer cases and almost 10 million cancer deaths worldwide in 2020, with the most commonly diagnosed cancers being female breast cancer and lung cancer, and the most common causes of cancer death being lung cancer and liver cancer.

INTERNATIONAL JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Pancreatic Adenocarcinoma, Version 2.2021

Margaret A. Tempero et al.

Summary: Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, with a major challenge being advanced disease at diagnosis. While survival rates have not significantly changed, newer treatments, including targeted therapies, offer hope for patients. The manuscript focuses on systemic therapy approaches for locally advanced and metastatic disease.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

EUS-guided placement of fiducial markers for stereotactic body radiation therapy in pancreatic cancer: feasibility, security and a new quality score

Mariana Figueiredo et al.

Summary: The study demonstrated the feasibility and safety of EUS-guided fiducial placement for SBRT treatment in PDAC patients. The newly proposed quality score may help improve fiducial positioning and SBRT delivery.

ENDOSCOPY INTERNATIONAL OPEN (2021)

添加到收藏夹

Article Oncology

Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1)

Alessandra Arcelli et al.

ANTICANCER RESEARCH (2020)

添加到收藏夹

Review Oncology

Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis

Leila T. Tchelebi et al.

CANCER (2020)

添加到收藏夹

Article Oncology

Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial

Eva Versteijne et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer

Soumon Rudra et al.

CANCER MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial)

Mustafa Suker et al.

ECLINICALMEDICINE (2019)

添加到收藏夹

Article Oncology

Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer

Xiaofei Zhu et al.

CANCER MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

T. Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma

Kimmen Quan et al.

PRACTICAL RADIATION ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review

Susanna W. L. de Geus et al.

CANCER (2017)

添加到收藏夹

Article Medicine, General & Internal

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib The LAP07 Randomized Clinical Trial

Pascal Hammel et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

添加到收藏夹

Article Oncology

Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Edward P. Balaban et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Medicine, General & Internal

Pancreatic cancer

Jorg Kleeff et al.

NATURE REVIEWS DISEASE PRIMERS (2016)

添加到收藏夹

Article Oncology

Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma

Joseph M. Herman et al.

CANCER (2015)

添加到收藏夹

Article Oncology

Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

Patrick J. Loehrer et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

添加到收藏夹

Article Medicine, General & Internal

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.